| __timestamp | Eli Lilly and Company | Vericel Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 6620800000 | 13774000 |
| Thursday, January 1, 2015 | 6533000000 | 22479000 |
| Friday, January 1, 2016 | 6452000000 | 27388000 |
| Sunday, January 1, 2017 | 6588100000 | 35610000 |
| Monday, January 1, 2018 | 5975100000 | 49007000 |
| Tuesday, January 1, 2019 | 6213800000 | 61139000 |
| Wednesday, January 1, 2020 | 6121200000 | 68836000 |
| Friday, January 1, 2021 | 6431600000 | 97592000 |
| Saturday, January 1, 2022 | 6440400000 | 106903000 |
| Sunday, January 1, 2023 | 6941200000 | 120998000 |
| Monday, January 1, 2024 | 8593800000 |
Unleashing the power of data
In the world of pharmaceuticals and biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Eli Lilly and Company and Vericel Corporation have demonstrated contrasting approaches to SG&A efficiency.
Eli Lilly, a pharmaceutical giant, has consistently maintained high SG&A expenses, averaging around $6.4 billion annually from 2014 to 2023. Despite this, their expenses have shown a modest growth of approximately 5% over the decade, reflecting a stable cost management strategy.
In contrast, Vericel Corporation, a smaller biotech firm, has seen its SG&A expenses skyrocket by nearly 800% during the same period, from $13.8 million in 2014 to $121 million in 2023. This dramatic increase highlights Vericel's aggressive expansion and investment in administrative capabilities.
Understanding these trends provides valuable insights into the strategic priorities of these companies.
Selling, General, and Administrative Costs: Eli Lilly and Company vs Pharming Group N.V.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Axsome Therapeutics, Inc.
Comparing SG&A Expenses: Eli Lilly and Company vs Merus N.V. Trends and Insights
Breaking Down SG&A Expenses: argenx SE vs Vericel Corporation
Operational Costs Compared: SG&A Analysis of Teva Pharmaceutical Industries Limited and Vericel Corporation
Dr. Reddy's Laboratories Limited and Vericel Corporation: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Amneal Pharmaceuticals, Inc. vs Vericel Corporation
Operational Costs Compared: SG&A Analysis of Vericel Corporation and Soleno Therapeutics, Inc.
Selling, General, and Administrative Costs: Vericel Corporation vs Dynavax Technologies Corporation
Comparing SG&A Expenses: Vericel Corporation vs Wave Life Sciences Ltd. Trends and Insights
Breaking Down SG&A Expenses: Vericel Corporation vs Agios Pharmaceuticals, Inc.
Vericel Corporation vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends